$2M USD DRUG ABOUT TO HIT U.S. MARKET

According to a report by the Wall Street Journal, a new gene therapy drug by Novartis is set to hit the U.S. market. The drug, Zolgensma, has the potential to cure spinal muscular atrophy, an inherited disease that often kills babies before their second birthday. Between 400 and 500 babies are born each year in the U.S. with the disease. Unsurprisingly, the arrival of the drug has brought up concerns about cost.